Trial of (+)-cyanidanol-3 in patients with hepatitis B chronic liver disease.
A double-blind controlled trial of 12 months' treatment with (+)-cyanidanol-3 was carried out in 26 patients with chronic hepatitis B liver disease. Treatment did not improve liver blood tests nor histological appearances of the liver, but there was a trend towards reduction of serum titres of hepatitis B surface antigen.
D002392:Catechin / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000503:physiopathology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008297:Male
D006514:Hepatitis B Surface Antigens; D002392:Catechin